Literature DB >> 8022865

Inhibition of the glycolytic enzymes in the trypanosome: an approach in the development of new leads in the therapy of parasitic diseases.

J Perie1, I Riviere-Alric, C Blonski, T Gefflaut, N Lauth de Viguerie, M Trinquier, M Willson, F R Opperdoes, M Callens.   

Abstract

Glycolysis in the trypanosome represents an important target for the development of new therapeutic agents due to the fact that this metabolism is essential for the parasite, glucose being its sole source of energy. In addition, different features of this metabolism and those associated with glycolytic enzymes offer opportunities for the development of efficient and selective compounds. Examples are given in this work of inhibitors directed to the enzymes aldolase and glyceraldehyde-phosphate-dehydrogenase and also of molecules acting specifically on the clusters of basic amino-acids present at the surfaces of the glycolytic enzymes in the parasite.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8022865     DOI: 10.1016/0163-7258(93)90016-7

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  2 in total

1.  Multiplex inhibitor screening and kinetic constant determinations for yeast hexokinase using mass spectrometry based assays.

Authors:  Hong Gao; Julie A Leary
Journal:  J Am Soc Mass Spectrom       Date:  2003-03       Impact factor: 3.109

2.  HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.

Authors:  Mckayla Stevens; Sanofar Abdeen; Nilshad Salim; Anne-Marie Ray; Alex Washburn; Siddhi Chitre; Jared Sivinski; Yangshin Park; Quyen Q Hoang; Eli Chapman; Steven M Johnson
Journal:  Bioorg Med Chem Lett       Date:  2019-02-28       Impact factor: 2.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.